PAVE Act
- Sponsor
- Rep. Griffith, H. Morgan [R-VA-9]
- Committees
- Ways and Means Committee (primary)
- Last action
- Oct 10, 2025
Bottom line
The PAVE Act aims to improve patient outcomes and antibiotic stewardship by integrating routine penicillin allergy verification into standard Medicare preventive care.
What it actually does
This bill, known as the PAVE Act, amends the Social Security Act to require Medicare to cover penicillin allergy verification and evaluation as part of both the initial preventive physical examination and the annual wellness visit. This evaluation includes identifying individuals with reported penicillin allergies, assessing the consistency of their reaction history with a true allergy, providing information on the impact of a penicillin allergy label, and referring patients to specialists if appropriate.
Proponents argue
Proponents argue that millions of patients are mislabeled with penicillin allergies, leading to the use of less effective or more expensive antibiotics, increased hospital stays, higher infection rates, and overall increased mortality. They cite extensive medical research showing that over 90% of self-reported penicillin allergies can be disproved, making this a cost-saving intervention that improves patient safety and public health by promoting appropriate antibiotic use.
Opponents contend
Opponents might contend that while the goal is laudable, expanding Medicare services could increase administrative burdens on healthcare providers and potentially lead to higher initial costs for the Medicare program. They may also raise concerns about the practical implementation of these evaluations within the existing time constraints of preventive visits, and whether primary care providers have adequate training or resources to conduct these initial verifications effectively without over-referring to specialists.
The bill is short and clearly written, making it highly accessible for any reader to understand its provisions and implications quickly.
Section 3(a) and (b)
Inclusion of Penicillin Allergy Verification and Evaluation in Medicare Preventive Services
This provision mandates that Medicare's initial preventive physical examination (IPPE) and annual wellness visits (AWV) must include a 'penicillin allergy verification and evaluation.' This evaluation involves identifying patients who believe they are allergic to penicillin, reviewing their reported reaction history to determine if it aligns with a true allergy, educating them on the health implications of an allergy label, and referring them to an allergy or immunology specialist if further testing or consultation is needed.
Supporters argue
Supporters argue that this provision directly addresses a widespread public health issue where false penicillin allergy labels lead to suboptimal patient care, increased healthcare costs, and contribute to antibiotic resistance. By integrating verification into routine preventive care, it leverages existing patient touchpoints to proactively identify and correct these mislabels, thereby enhancing patient safety and promoting better antibiotic stewardship.
Critics contend
Critics might argue that while beneficial, mandating this service within existing preventive visit structures could strain provider time and resources, potentially detracting from other important aspects of the comprehensive examination. They may also question whether primary care providers are adequately equipped to perform the initial verification steps without extensive additional training, leading to either perfunctory checks or an excessive number of specialist referrals.
Tradeoffs
The bill balances the significant public health benefits of correcting mislabeled penicillin allergies against the potential for increased administrative burden on healthcare providers and initial costs to the Medicare system. It aims to achieve long-term health and economic benefits by investing in a preventive measure that could reduce more costly complications down the line.
Section 3(c)
Rule of Construction for Separate Payment
This section clarifies that the bill's amendments do not prevent separate Medicare payment for more extensive 'structured penicillin allergy validation and evaluation services' if they are provided on the same day as an initial preventive physical examination or an annual wellness visit. This distinguishes the basic 'verification and evaluation' now included in preventive visits from more in-depth, separately billable services.
The amendments made by this Act will take effect for examinations and visits furnished on or after January 1, 2027.
Section 3(d)
Why it matters:This is standard legislative practice for specifying the implementation timeline of a bill's provisions.
Case for: The delayed effective date provides healthcare providers, Medicare administrators, and patients with ample time to prepare for the new requirements, develop necessary protocols, and disseminate information. This ensures a smoother transition and more effective implementation of the new preventive service.
Case against: Some might argue that delaying the implementation until 2027 postpones the realization of significant public health benefits and cost savings that could be achieved sooner by correcting mislabeled penicillin allergies. Given the urgency highlighted in the findings, an earlier effective date could be beneficial.
Estimated impact: The delay impacts when the benefits of the bill (improved patient outcomes, antibiotic stewardship) and its costs (Medicare expenditures, administrative burden) will begin to accrue.